A new crop of companies deals head-on with Big Pharma's biggest out-licensing problems--transaction cost and the "embarrassment factor." Solving both involves strategies to make the extra work of out-licensing worthwhile for their large partners. In particular, after years of resisting the idea, they're now allowing their Big Pharma partners the right to buy back the compounds, usually after clinical proof of concept.
By Roger Longman
The drug industry should be in the heyday of Big Pharma out-licensing. Pharmaceutical companies, as a group under the worst...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.
